Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0222 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0222 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0222 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0197 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0222 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0137 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0222 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.011 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0222 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0222 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0197 | 0.7743 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0222 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.011 | 0 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0222 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0222 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0222 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0222 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0137 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0222 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0222 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0222 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0222 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0222 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0222 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0222 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0222 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0222 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0222 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0112 | 0.0151 | 0.0151 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Inhibition of phenylephrine-stimulated Wistar rat aorta contraction at 10 uM | ChEMBL. | 16513345 | |
Activity (functional) | Inhibition of phenylephrine-stimulated Wistar rat aorta contraction at 100 uM | ChEMBL. | 16513345 | |
Activity (functional) | 0 | Inhibition of phenylephrine-stimulated Wistar rat aorta contraction at 10 uM | ChEMBL. | 16513345 |
Activity (functional) | 0 | Inhibition of phenylephrine-stimulated Wistar rat aorta contraction at 100 uM | ChEMBL. | 16513345 |
Activity (functional) | = 45.9 % | Anxiolytic effect in Albino ICR mouse assessed as number of entries in open arms of elevated plus-maze test at 15 mg/kg, ip | ChEMBL. | 17507222 |
Activity (functional) | = 45.9 % | Anxiolytic effect in Albino ICR mouse assessed as number of entries in open arms of elevated plus-maze test at 15 mg/kg, ip | ChEMBL. | 17507222 |
Activity (functional) | = 48.7 % | Anxiolytic effect in Albino ICR mouse assessed as time spent on open arms of elevated plus-maze test at 15 mg/ kg, ip | ChEMBL. | 17507222 |
Activity (functional) | = 48.7 % | Anxiolytic effect in Albino ICR mouse assessed as time spent on open arms of elevated plus-maze test at 15 mg/ kg, ip | ChEMBL. | 17507222 |
EC50 (functional) | Vasorelaxation of phenylephrine-stimulated Wistar rat aorta contraction | ChEMBL. | 16513345 | |
EC50 (functional) | Vasorelaxation of noradrenaline-stimulated Wistar rat vas deferens contraction | ChEMBL. | 16513345 | |
EC50 (functional) | 0 | Vasorelaxation of phenylephrine-stimulated Wistar rat aorta contraction | ChEMBL. | 16513345 |
EC50 (functional) | 0 | Vasorelaxation of noradrenaline-stimulated Wistar rat vas deferens contraction | ChEMBL. | 16513345 |
IC50 (functional) | = 38 ug ml-1 | In vitro inhibitory concentration against Plasmodium falciparum (F32) | ChEMBL. | 12873511 |
IC50 (functional) | = 38 ug ml-1 | In vitro inhibitory concentration against Plasmodium falciparum (F32) | ChEMBL. | 12873511 |
IC50 (functional) | >= 100 ug ml-1 | In vitro inhibitory activity against Leishmania braziliensis (M2903) | ChEMBL. | 11514152 |
IC50 (functional) | >= 100 ug ml-1 | In vitro inhibitory activity against Leishmania amazonensis (PH8) | ChEMBL. | 11514152 |
IC50 (functional) | >= 100 ug ml-1 | In vitro inhibitory activity against Leishmania donovani (PP75) | ChEMBL. | 11514152 |
IC50 (functional) | > 100 ug ml-1 | Inhibitory concentration against epimastigotes (Tulahuen strain) of Trypanosoma cruzi; Inactive | ChEMBL. | 11591517 |
IC50 (functional) | > 100 ug ml-1 | Inhibitory concentration against trypomastigotes (Y strain) of Trypanosoma cruzi; Inactive | ChEMBL. | 11591517 |
IC50 (functional) | >= 100 ug ml-1 | In vitro inhibitory activity against Leishmania braziliensis (M2903) | ChEMBL. | 11514152 |
IC50 (functional) | >= 100 ug ml-1 | In vitro inhibitory activity against Leishmania donovani (PP75) | ChEMBL. | 11514152 |
IC50 (functional) | > 100 ug ml-1 | Inhibitory concentration against epimastigotes (Tulahuen strain) of Trypanosoma cruzi; Inactive | ChEMBL. | 11591517 |
IC50 (functional) | > 100 ug ml-1 | Inhibitory concentration against trypomastigotes (Y strain) of Trypanosoma cruzi; Inactive | ChEMBL. | 11591517 |
IC50 (functional) | = 104 uM | In vitro inhibitory concentration against Plasmodium falciparum (F32) | ChEMBL. | 12873511 |
IC50 (functional) | = 104 uM | In vitro inhibitory concentration against Plasmodium falciparum (F32) | ChEMBL. | 12873511 |
Index (functional) | < 0.1 % | Antiplasmodial potency of the compound measured relative to chloroquine (IC50 chloroquine / IC50 compound) | ChEMBL. | 12873511 |
Index (functional) | < 0.1 % | Antiplasmodial potency of the compound measured relative to chloroquine (IC50 chloroquine / IC50 compound) | ChEMBL. | 12873511 |
Inhibition (functional) | Inhibition of noradrenaline-stimulated Wistar rat vas deferens contraction at 1 uM | ChEMBL. | 16513345 | |
Inhibition (functional) | Inhibition of noradrenaline-stimulated Wistar rat vas deferens contraction at 10 uM | ChEMBL. | 16513345 | |
Inhibition (functional) | 0 | Inhibition of noradrenaline-stimulated Wistar rat vas deferens contraction at 1 uM | ChEMBL. | 16513345 |
Inhibition (functional) | 0 | Inhibition of noradrenaline-stimulated Wistar rat vas deferens contraction at 10 uM | ChEMBL. | 16513345 |
pD'2 (binding) | Affinity to Adrenergic alpha1B receptor in Wistar rat spleen | ChEMBL. | 16513345 | |
pD'2 (binding) | Affinity to Adrenergic alpha1D receptor in Wistar rat aorta | ChEMBL. | 16513345 | |
pD'2 (binding) | Affinity to Adrenergic alpha1A receptor in Wistar rat vas deferens | ChEMBL. | 16513345 | |
pD'2 (binding) | 0 | Affinity to Adrenergic alpha1A receptor in Wistar rat vas deferens | ChEMBL. | 16513345 |
pD'2 (binding) | 0 | Affinity to Adrenergic alpha1B receptor in Wistar rat spleen | ChEMBL. | 16513345 |
pD'2 (binding) | 0 | Affinity to Adrenergic alpha1D receptor in Wistar rat aorta | ChEMBL. | 16513345 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
5 literature references were collected for this gene.